Trial register facet
Trial records in type 2 diabetes mellitus — page 10
247 records bearing on type 2 diabetes mellitus.
Showing 0 records on this page
Records
247 documents · page 10 of 11
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| LEAD-6-ADHERENCEprogramme record | Liraglutide | Phase 3 | Reported | Observational | — | 2009 | Very low |
| LEAD-6-DDIprogramme record | Liraglutide | Phase 1 | Reported | Randomised crossover | — | 2009 | Very low |
| DURATION-1 | Exenatide | Phase 3 | Reported | Randomised, open-label, active-controlled | 295 | 2008 | High |
| DURATION-1-ELDERLYprogramme record | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2008 | Very low |
| DURATION-1-OLEprogramme record | Exenatide | Phase 3 | Reported | Single-arm open-label | — | 2008 | Very low |
| DURATION-1-ADHERENCEprogramme record | Exenatide | Phase 3 | Reported | Observational | — | 2008 | Very low |
| DURATION-1-BIOMARKERprogramme record | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2008 | Very low |
| DURATION-1-HEPATIC-IMPprogramme record | Exenatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2008 | Very low |
| AMIGO-1 | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 377 | 2005 | High |
| AMIGO-1-RENAL-IMPprogramme record | Exenatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2005 | Very low |
| AMIGO-1-PKprogramme record | Exenatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2005 | Very low |
| AMIGO-1-DDIprogramme record | Exenatide | Phase 1 | Reported | Randomised crossover | — | 2005 | Very low |
| AMIGO-1-HEPATIC-IMPprogramme record | Exenatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2005 | Very low |
| AMIGO-1-REGIONAL-JPprogramme record | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2005 | Very low |
| PRAM-T2D-1YR | Pramlintide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 656 | 2003 | Moderate |
| PRAM-T2D-1YR-HEPATIC-IMPprogramme record | Pramlintide | Phase 1 | Reported | Phase 1 ascending dose | — | 2003 | Very low |
| PRAM-T2D-1YR-DDIprogramme record | Pramlintide | Phase 1 | Reported | Randomised crossover | — | 2003 | Very low |
| PRAM-T2D-1YR-PKprogramme record | Pramlintide | Phase 1 | Reported | Phase 1 ascending dose | — | 2003 | Very low |
| PRAM-T2D-1YR-RENAL-IMPprogramme record | Pramlintide | Phase 1 | Reported | Phase 1 ascending dose | — | 2003 | Very low |
| TRIUMPH-2 | Retatrutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Not rated |
| SYNCHRONIZE-2 | Survodutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Not rated |
| DREAMS-3 | Mazdutide | Phase 3 | Ongoing | Randomised, double-blind, active-controlled | — | — | Not rated |
| TRIUMPH-2-REGIONAL-CNprogramme record | Retatrutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Very low |
| SYNCHRONIZE-2-REGIONAL-JPprogramme record | Survodutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Very low |
page 10 of 11